Dermatomyositis Trials in New York, United States
Conditions / Dermatomyositis / New York, United States
Clinical trials for Dermatomyositis investigate a range of treatment strategies and patient populations.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03813160 | Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis | COMPLETED | PHASE3 |
| NCT06154252 | RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy | RECRUITING | — |
| NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | RECRUITING | — |
| NCT04999020 | Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis | TERMINATED | PHASE2/PHASE3 |
| NCT02971683 | Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy | COMPLETED | PHASE3 |
| NCT06154252 | RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy | RECRUITING | — |
| NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | RECRUITING | — |
| NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | RECRUITING | — |
| NCT05523167 | A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. | ACTIVE_NOT_RECRUITING | PHASE2/PHASE3 |
| NCT05437263 | A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis | ACTIVE_NOT_RECRUITING | PHASE3 |